Wilson disease: Genetic basis of copper toxicity and natural history

Seminars in Liver Disease

Volumn 16, Issue 1, 1996, Pages 83-95

  Schilsky, Michael L ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; ALBUMIN; ALKALINE PHOSPHATASE; BILIRUBIN; CERULOPLASMIN; COPPER; DIAMINE; DIANISIDINE; DIMERCAPROL; GENE PRODUCT; GLUTATHIONE; LIPID; METALLOTHIONEIN; MITOCHONDRIAL DNA; PENICILLAMINE; PROTEIN; TETRATHIOMOLYBDIC ACID; TRIENTINE; ZINC DERIVATIVE;

CHELATION; COPPER METABOLISM; ELECTRON MICROSCOPY; GENE; GENE MUTATION; GENE THERAPY; HEPATITIS; HUMAN; INTRAMUSCULAR DRUG ADMINISTRATION; LIPID PEROXIDATION; LIVER BIOPSY; LIVER TRANSPLANTATION; MENTAL DISEASE; NEUROLOGIC DISEASE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; ORAL DRUG ADMINISTRATION; PREGNANCY; PRIORITY JOURNAL; REVIEW; TOXICITY; WILSON DISEASE;

ADENOSINE TRIPHOSPHATASES; CARRIER PROTEINS; CATION TRANSPORT PROTEINS; CHELATING AGENTS; CHELATION THERAPY; CHROMOSOME MAPPING; COPPER; ENVIRONMENT; GENE THERAPY; GENOME, HUMAN; HEPATITIS; HEPATOLENTICULAR DEGENERATION; HUMANS; LIVER TRANSPLANTATION; MOLYBDENUM; MUTATION; PENICILLAMINE; RISK FACTORS; TRIETHYLENETETRAMINE; ZINC;

EID: 0029874633     PISSN: 02728087     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2007-1007221     Document Type: Article

References (93)

1. Scheinberg IH, Sternlieb I: Wilson's disease. Philadelphia, WB Saunders Co, 1984.
2. Frydman M, Bonne-Tammir B, Farrer LA, et al: Assignment of the gene for Wilson disease to chromosome 13: Linkage to the esterase D locus. Proc Natl Acad Sci 82:1819-21, 1985.
3. Bowcock AM, Farrer LA, Hebert JM, et al: Eight closely linked loci place the Wilson disease locus within 13q14-q21. Am J Hum Genet 43:664-74, 1988.
4. Farrer LA, Bowcock AM, Hebert JM, et al: Predictive testing for Wilson's disease using tightly linked and flanking DNA markers. Neurology 41:992-9, 1991.
5. White A, Tomfohrde J, Stewart E, et al: A 45 megabase yeast artificial chromosome antigen from human chromosome 13q14.3 ordering 9 polymorphic microsatellites (22 sequence-tagged sites) tightly linked to the Wilson's disease locus. Proc Natl Acad Sci 90:10105-9, 1993.
6. Tanzi RE, Petrukhin K, Chernov I, et al: The Wilson disease gene is a copper transporting ATPase with homology to the Menkes disease gene. Nat Genet 5:344-50, 1993.
7. Petrukhin K, Fischer SG, Pirastu M, et al: Mapping, cloning and genetic characterization of the region containing the Wilson disease gene. Nat Genet 5:338-43, 1993.
8. Bull PC, Thomas GR, Rommens JM, et al: The Wilson disease gene is a putative copper transporting P-type ATPase similar to the Menkes gene. Nat Genet 5:327-37, 1993.
9. Yamaguchi Y, Heiny ME, Gitlin JD: Isolation and characterization of a human liver cDNA as a candidate gene for Wilson disease. Biochem Biophys Res Commun 197:271-7, 1993.
10. Petrukhin K, Lutsenko S, Chernov I, et al: Characterization of the Wilson disease gene encoding a P-type copper transporting ATPase: genomic organization, alternative splicing, and structure/function predictions. Hum Mol Genet 3:1647-56, 1994.
11. Solioz M, Odermatt A, Krapf R: Copper pumping ATPases: common concepts in bacteria and man [Review]. FEBS Lett 346:44-7, 1994.
12. Thomas GR, Forbes JR, Roberts EA, et al: The Wilson disease gene: spectrum of mutations and their consequences. Nat Genet 9:210-7, 1995.
13. Cousins RJ: Absorption, transport, and hepatic metabolism of copper and zinc: special reference to metallothionein and ceruloplasmin. Physiol Rev 65:238-309, 1985.
14. Danks DM: Disorders of copper metabolism. In: The metabolic basis of inherited disease. Scriver CR, Beaudet AL, Sly WS, Valle D (eds). Vol 1. New York, McGraw Hill 1:1411-31, 1989
15. Sarkar B: In: Metal-ligand interactions in organic chemistry and biochemistry. (Pullman B, Goldblum N, eds). D. Reidel Publishing Co, Dordrecht, 1977, pp 198-238.
16. Lan SJ, Laussac JP, Sarkar B: Synthesis and copper (II) binding properties of the N-terminal peptide of human β-α-fetoprotein. Biochem J 257:745-50, 1989.
17. Freedman JH, Ciriolo MR, Peisach J: The role of glutathione in copper metabolism and toxicity. J Biol Chem 264:5598-605, 1989.
18. Yamada T, Agui Y, Suzuki Y, Sato M, Matsumoto K: Inhibition of the copper incorporation into ceruloplasmin leads to the deficiency in serum ceruloplasmin activity in Long-Evans Cinnamon mutant rat. J Biol Chem 268:8965-71, 1993.
19. Holtzman NA, Gaumnitz BM: Studies on the rate of release and turnover of ceruloplasmin and apoceruloplasmin in rat plasma. J Biol Chem 245:2350-3, 1970.
20. Li Y, Togashi Y, Sato S, et al: Spontaneous hepatic copper accumulation in Long-Evans Cinnamon rats with hereditary hepatitis. A model of Wilson's disease. J Clin Invest 87:1858-61, 1991.
21. Murata Y, Yamakawa E, Iizuka T, et al: Failure of copper incorporation into ceruloplasmin in the Golgi apparatus of LEC rat hepatocytes. Biochem Biophys Res Commun 209:349-55, 1995.
22. Terada K, Kawarda Y, Muira N, et al: Copper incorporation into ceruloplasmin in rat livers. Biochim Biophys Acta 1270:58-62, 1995.
23. Frommer DJ: Defective biliary excretion of copper in Wilson's disease. Gut 15:125-9, 1974.
24. O'Reilly S, Weber PM, Oswald M, Slupley L: Abnormalities of the physiology of copper. Arch Neurol 25:28-32, 1971.
25. Sternlieb I, van den Hamer CJA, Morell AG, et al: Lysosomal defect of hepatic copper excretion in Wilson's disease (hepatolenticular degeneration). Gastroenterology 64:99-105, 1973.
26. Gollan JL, Deller DT: Studies on the nature and excretion of biliary copper in man. Clin Sci 44:9-15, 1973.
27. Sternlieb I. Copper and zinc. In: The liver: biology and pathobiology. Arias IM, Boyer JL, Fausto N, Jakoby WB, Schachter D, Shafritz DA, (eds). Raven Press, New York 3:585-96, 1994.
28. Lewis KO: The nature of the copper complexes in bile and their relationship to the absorption and excretion of copper in normal subjects and in Wilson's disease. Gut 14:221-32, 1973.
29. Gross JB, Myers BM, Kost LJ, et al: Biliary copper excretion by hepatic lysosomes in the rat. Major excretory pathway in experimental copper overload. J Clin Invest 83:30-9, 1989.
30. Harada M, Sakisaka S, Yoshitake M, et al: Biliary copper excretion in acutely and chronically copper-loaded rats. Hepatology 17:111-7, 1993.
31. Houwen R, Dijkstra M, Kuipers F, et al: Two pathways for biliary copper excretion in the rat. Biochem Pharmacol 39:1039-44, 1990.
32. Dijkstra M, Veld GI. van den Berg GJ, et al: Adenosine triphosphate-dependent copper transport in isolated rat liver plasma membranes. J Clin Invest 95:412-6.
33. Schilsky ML: In vitro modelling of liver membrane copper transport. Hepatology 22:1341-3, 1995.
34. Evans GW, Cornatzer WE: Biliary copper excretion in the rat. Proc Soc Exp Biol Med 136:719-21, 1971.
35. Sugawara N, Li D, Katakura M, Sugawara C: Biliary excretion of copper in Fischer rats treated with copper salt and in Long-Evans Cinnamon (LEC) rats with an inherently abnormal copper metabolism. Bio! Trace Elem Res 46:125-34, 1994.
36. Schilsky ML, Stockert RJ, Sternlieb I: Pleiotropic effect of the LEC mutation: a rodent model of Wilson's disease. Am J Physiol 266:G907-13, 1994.
37. Kaushansky A, Frydman M, Kaufman H, Jomberg R: Endocrine studies of the ovulatory disturbances in Wilson's disease (hepatolenticular degeneration). Fertil Steril 47:270-3, 1987.
38. Cairns JE, Williams HP, Walshe JM: "Sunflower cataract" in Wilson's disease. BMJ 3:95-6, 1969.
39. Beam AG, McKusick VA: Azure lunulae. An unusual change in the fingernails in two patients with hepatolenticular degeneration (Wilson's disease). JAMA 166:904-6, 1958.
40. Schilsky ML, Scheinberg IH, Sternlieb I: Liver transplantation for Wilson's disease: indications and outcome. Hepatology 19:583-7, 1994.
41. Denny-Brown D: Hepatolenticular degeneration (Wilson's disease): two different components. N Engl J Med 270:1149-56, 1964.
42. Walshe JM, Yealland M. Wilson's disease: the problem of delayed diagnosis. J Neurol, Neurosurg, Psychiatry 55:692-6, 1992.
43. Walshe JM, Yealland M: Chelational treatment of neurological Wilson's disease. Q J Med 86:197-204, 1993.
44. Starosta-Rubinstein S, Young AB, Kluin K, et al: Clinical assessment of 31 patients with Wilson's disease: correlations with structural changes on magnetic resonance imaging. Arch Neurol 44:365-70, 1987.
45. Prayer L, Wumberger D, Kramer J, et al: Cranial MRI in Wilson's disease. Neuroradiology 32:211-4, 1990.
46. Oder W, Prayer L, Grimm F, et al: Wilson's disease: evidence of subgroups derived from clinical findings and brain lesions. Neurology 43:120-4, 1993.
47. Grimm G, Prayer L, Oder W, et al: Comparison of functional and structural brain disturbances in Wilson's disease. Neurology 41:212-6, 1991.
48. Selwa LM, Vanderzant CW, Brumberg JA, et al: Correlation of evoked potential and MRI findings in Wilson's disease. Neurology 43:2059-64, 1993.
49. Nazer H, Brismar J, Al-Kawi MZ, et al: Magnetic resonance imaging of the brain in Wilson's disease. Neuroradiology 35:130-3, 1993.
50. Roh JK, Lee TG, Wie BA, et al: Initial and follow-up brain MRI findings and correlation with the clinical course in Wilson's disease. Neurology 44:1064-8, 1994.
51. Ross ME, Jacobson IM, Dienstag JL, Martin JB: Late-onset Wilson's disease with neurological involvement in the absence of Kayser-Fleischer rings. Ann Neurol 17:411-3, 1985.
52. Willeit J, Kiechl SG: Wilson's disease with neurological impairment but no Kayser-Fleischer rings. Lancet 337:1426, 1991 (letter).
53. Fleming CR, Dickson ER, Wahner HW, et al: Pigmented corneal rings in non-Wilsonian liver disease. Ann Intern Med 86:285-8, 1977.
54. Tauber J, Steinert RF: Pseudo-Kayser-Fleischer ring of the cornea associated with non-Wilsonian liver disease. A case report and literature review. Cornea 12:74-7, 1993.
55. Scheinberg IH, Gitlin D: Deficiency of ceruloplasmin in patients with hepatolenticular degeneration (Wilson's disease). Science 116:484-5, 1952.
56. Edwards CQ, Williams DM, Cartwright GE: Hereditary hypoceruloplasminemia. Clin Gen 15:311-6, 1979.
57. Harris LZ, Takahashi Y, Miyajima H, et al: Aceruloplasminemia: molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci 92:2539-43, 1995.
58. Yoshida K, Furihata K, Takeda S, et al: A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat Gen 9:268-72, 1995.
59. Martins da Costa C, Baldwin D, Portmann B, et al: Value of urinary copper excretion after penicillamine challenge in the diagnosis of Wilson's disease. Hepatology 15-609-15, 1992.
60. Sternlieb I: Mitochondrial and fatty changes in hepatocytes of patients with Wilson's disease. Gastroenterology 55:354-67, 1968.
61. Goldfischer S, Sternlieb I: Changes in the distribution of hepatic copper in relation to the progression of Wilson's disease (hepatolenticular degeneration). Am J Pathol 53:883-901, 1968.
62. Alt E, Sternlieb I, Goldfischer S: The cytopathology of metal overload [review]. Int Rev Exp Pathol 31:165-88, 1990.
63. Sternlieb I: Fraternal concordance of types of abnormal hepatocellular mitochondria in Wilson's disease. Hepatology 16:728-32, 1992.
64. Sternlieb I, Scheinberg IH: The role of radiocopper in the diagnosis of Wilson's disease. Gastroenterology 77:138-42, 1979.
65. Shaver WA, Bhatt H, Combes B: Low serum alkaline phosphatase activity in Wilson's disease. Hepatology 6:859-63, 1986.
66. Wilson RA, Clayson KJ, Leon S: Unmeasurable serum alkaline phosphatase activity in Wilson's disease associated with fulminant hepatic failure and hemolysis. Hepatology 7:613-5, 1987.
67. McCullough AJ, Fleming CR, Thistle JL, et al: Diagnosis of Wilson's disease presenting as fulminant hepatic failure. Gastroenterology 84:161-7, 1983.
68. Berman DH, Leventhal RI, Gavaler JS, et al: Clinical differentiation of fulminant Wilsonian hepatitis from other causes of hepatic failure. Gastroenterology 100:1129-34, 1991.
69. Sallie R, Katsiyiannakis L, Baldwin D, et al: Failure of simple biochemical indexes to reliably differentiate fulminant Wilson's disease from other causes of fulminant liver failure. Hepatology 16:1206-11, 1992.
70. Cumings JN: The effects of BAL in hepatolenticular degeneration. Brain 74:10-22, 1951.
71. Denny-Brown D, Porter H: The effect of BAL (2,3 dimercaptopropanol) on hepatolenticular degeneration (Wilson's disease). N Engl J Med 245:917-25, 1951.
72. Walshe JM: Penicillamine: a new oral therapy for Wilson's disease. Am J Med 21:487-95, 1956.
73. Walshe JM: Copper chelation in Wilson's disease. A comparison of penicillamine and triethylene tetramine dihydrochloride. Q J Med 42:441-52, 1973.
74. Goonerame SR, Howell JMC, Gawthorne JM: An investigation of the effects of intravenous administration of thiomolybdate on copper metabolism in chronic Cu poisoned sheep. Br J Nutr 46:46, 1981.
75. Schilsky ML, Scheinberg IH, Sternlieb I: Prognosis of Wilsonian chronic active hepatitis. Gastroenterology 100:762-7, 1991.
76. Bellary S, Hassanein T, Van Thiel DH: Liver transplantation for Wilson's disease. J Hepatol 23:373-81, 1995.
77. Rakela J, Kurtz SB, McCarthy JT, et al: Fulminant Wilson's disease treated with postdilution hemofiltration and orthotopic liver transplantation. Gastroenterology 90:2004-7, 1986.
78. Denis J, Guerin JM, Opolon P, et al: Hemofiltration with a high permeability membrane in the treatment of fulminant or end-stage Wilson's disease. ASA 10 J 6:36-43, 1983.
79. Scheinberg IH, Jaffe ME, Sternlieb I: The use of trientine in preventing the effects of interrupting penicillamine therapy in Wilson's disease. N Engl J Med 317:209-13, 1987.
80. Brewer GJ, Terry CA, Aisen AM, Hall GM: Worsening of neurologic syndrome in patients with Wilson's disease with metal penicillamine therapy. Arch Neurol 44:490-3, 1987.
81. Scheinberg IH, Sternlieb I: Treatment of the neurologic manifestations of Wilson's disease. Arch Neurol 52:339-40, 1995.
82. Brewer GJ, Dick RD, Yuzbasiyan-Gurkin V, et al: Initial therapy of patients with Wilson's disease with tetrathiomolybdate. Arch Neurol 48:42-7, 1991.
83. Brewer GJ, Dick RD, Johnson V, et al: Treatment of Wilson's disease with ammonium tetrathiomolybdate. I. Initial therapy in 17 neurologically affected patients. Arch Neurol 51:545-54, 1994.
84. 4) as an anti-copper agent in man. In: Orphan diseases and orphan drugs. Scheinberg IH, Walshe JM (eds). Manchester, Manchester University Press, 1986, pp 76-85.
85. Polson RJ, Rolles K, Calne RY, et al: Reversal of severe neurological manifestations of Wilson's disease following orthotopic liver transplantation. Q J Med 64:685-91, 1987.
86. Schilsky ML, Blank RR, Czaja MJ, et al: Hepatocellular copper toxicity and its attentuation by zinc. J Clin Invest 84:1562-8, 1989.
87. Hoogenraad TU, Koevoet R, de Ruyter Korver EG: Oral zinc sulphate as long-term treatment in Wilson's disease (hepatolenticular degeneration). Eur Neurol 18:205-11, 1979.
88. Brewer GJ, Dick RD, Yuzbasiyan-Gurkan V, et al: Treatment of Wilson's disease with zinc XIII. Therapy with zinc in presymp-tomatic patients from the time of diagnosis. J Lab Clin Med 123:849-58, 1994.
89. Collins JC, Scheinberg DH, Sternlieb I: Penicillamine prophylaxis for asymptomatic children with Wilson's disease. Hepatology 18:128A, 1993.
90. Scheinberg IH, Sternlieb I: Pregnancy in penicillamine treated patients with Wilson's disease. N Engl J Med 293:1300-2, 1975.
91. Walshe JM: Pregnancy in Wilson's disease Q J Med 181:73-83, 1977.
92. Walshe JM: The management of pregnancy in Wilson's disease treated with trientine. Q J Med 58:81-7, 1986.
93. Brewer JB, Yuzbasiyan-Gurkan V: Wilson's disease. Medicine 71:139-63, 1992.